Tuesday, January 12, 2010

ARCA Biopharma May Patent Methods to Treat Heart Failure

Colorado-based ARCA Biopharma has been given a "notice of allowance" by the U.S. Patent and Trademark Office for some methods to treat heart failure patients, officials for the biotechnology company announced Monday. Dailycamera.com reports that ARCA submitted the patent application, “Methods for Treatment with Bucindolol Based on Genetic Targeting,” to help the company in its genetically targeted therapies for patient with heart failure and other cardiovascular conditions.

Learn more: Broomfield-based ARCA Biopharma on verge of patent approval

Share this article with your social network, just click below to share now!

No comments :

Post a Comment